E/M Coding Alert - 2004 Issue 4
Medicare Rx: REALITY: MEDICARE MAY NEED TO SET SOME Rx PRICES
Subscribe or sign in to view the full article.
Article Overview
This article examines a Health Affairs-era discussion of Medicare prescription drug pricing policy and the future of the law’s non-interference provision. It is aimed at readers who follow Medicare policy, pharmaceutical pricing, and health economics. The piece summarizes broad arguments about when market-based negotiation may work, when government price-setting might be considered, and why pricing policy matters for access, coverage decisions, and innovation.
Why This Topic Matters
The article addresses a major Medicare policy issue: how prescription drug prices may be constrained when competition is limited. It is relevant to policymakers, payers, and coding/billing professionals who monitor Medicare coverage and pharmaceutical reimbursement policy.
What You Will Learn
- How Medicare prescription drug pricing policy is being debated in an economics and policy context.
- Why the non-interference provision is discussed as a potential obstacle to price negotiation in some situations.
- What broad concerns arise when drugs have little or no competition.
- How coverage policy and pricing policy may interact in federal health programs.
- Why pricing policy debates often include concerns about innovation and investment.
Who Should Read This
- Health policy analysts
- Medicare stakeholders
- Payers and plan administrators
- Pharmaceutical pricing and reimbursement professionals
- Health economists
- Coding and compliance teams tracking Medicare policy
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com